Moleculin Biotech, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Moleculin Biotech, Inc. (MBRX) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$7.03 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-18
- Moleculin Biotech, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$7.03M.
- Moleculin Biotech, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$5.43M, a 186.88% decline from fiscal 2023.
- Moleculin Biotech, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was $6.25M, a 2.54% increase from fiscal 2022.
- Moleculin Biotech, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was $6.10M, a 82.62% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$7.03M 10-K · filed 2026-03-18 | |
| 2024-12-31 | -$5.43M 10-K · filed 2026-03-18 | $4.57M 10-K · filed 2025-03-21 |
| 2023-12-31 | $6.25M 10-K · filed 2025-03-21 | |
| 2022-12-31 | $6.10M 10-K · filed 2024-03-22 | |
| 2021-12-31 | $3.34M 10-K · filed 2023-03-22 | |
| 2020-12-31 | $3.65M 10-K · filed 2022-03-24 | |
| 2019-12-31 | $2.77M 10-K · filed 2021-03-24 | -$2.77M 10-K · filed 2020-03-19 |
| 2018-12-31 | -$2.49M 10-K · filed 2020-03-19 | $2.49M 10-K · filed 2019-02-21 |
| 2017-12-31 | $3.33M 10-K · filed 2019-02-21 | -$3.33M 10-K · filed 2018-03-28 |
| 2016-12-31 | -$1.33M 10-K · filed 2018-03-28 | $1.33K 10-K · filed 2017-04-03 |
| 2015-12-31 | $254.00 10-K · filed 2017-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |